Recent discoveries of influenza A drug target sites to combat virus replication
Hershna Patel1, Andreas Kukol2
1School of Life and Medical Sciences, University of Hertfordshire, College Lane, Hatfield, AL10 9AB, U.K. h.patel28@herts.ac.uk.
Abstract:
Sequence variations in the binding sites of influenza A proteins are known to limit the effectiveness of current antiviral drugs. Clinically, this leads to increased rates of virus transmission and pathogenicity. Potential influenza A inhibitors are continually being discovered as a result of high-throughput cell based screening studies, whereas the application of computational tools to aid drug discovery has further increased the number of predicted inhibitors reported. This review brings together the aspects that relate to the identification of influenza A drug target sites and the findings from recent antiviral drug discovery strategies.
More Related Videos
09:07Using Zebrafish Models of Human Influenza A Virus Infections to Screen Antiviral Drugs and Characterize Host Immune Cell Responses
Published on: January 20, 2017
11:20Affinity Purification of Influenza Virus Ribonucleoprotein Complexes from the Chromatin of Infected Cells
Published on: June 3, 2012
Related Concept Videos
Influenza
Inhibitors of Viral Protein Synthesis
Leaky Scanning
Inhibitors of Bacterial DNA Synthesis
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Viruses with RNA Genomes
